Uploaded August 2022 | Updated November 2026, 17 hours ago
Charles Brenner
PhD at Stanford University, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism,
Charles Brenner is the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism in the Department of Diabetes & Cancer Metabolism. His laboratory focuses on disturbances in nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, in diseases and conditions of metabolic stress.
Among his most significant discoveries, he identified nicotinamide riboside (NR) as an unanticipated vitamin precursor of NAD. He also developed a quantitative metabolomic technology that allowed him and others to discover that the NAD system is disturbed by many diseases and conditions including diabetes, cancer and amyotrophic lateral sclerosis (ALS).
In this talk, Brenner will review what NAD is and does, what it known about disturbance of NAD systems in ALS and what data from mice and early stage clinical trials may mean for people living with ALS.
Charles Brenner
PhD at Stanford University, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism,
Charles Brenner is the Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism in the Department of Diabetes & Cancer Metabolism. His laboratory focuses on disturbances in nicotinamide adenine dinucleotide (NAD), the central catalyst of metabolism, in diseases and conditions of metabolic stress.
Among his most significant discoveries, he identified nicotinamide riboside (NR) as an unanticipated vitamin precursor of NAD. He also developed a quantitative metabolomic technology that allowed him and others to discover that the NAD system is disturbed by many diseases and conditions including diabetes, cancer and amyotrophic lateral sclerosis (ALS).
In this talk, Brenner will review what NAD is and does, what it known about disturbance of NAD systems in ALS and what data from mice and early stage clinical trials may mean for people living with ALS.










